Results of GSK and AstraZeneca trials may widen ovarian cancer drug use

Published 7y ago

BARCELONA (Reuters) – GlaxoSmithKline and AstraZeneca both reported trial results that will likely make their competing drugs available to a wider group of ovarian cancer patients, possibly helping GSK catch its rival in a highly contested drug class. The two ... More »